Observational studyThe European journal of neuroscience2026
Assessing the Clinical Relevance of Blood Soluble Triggering Receptor Expressed on Myeloid Cells 2 in Neurological Diseases.
Observational study in The European journal of neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Assessing the Clinical Relevance of Blood Soluble Triggering Receptor Expressed on Myeloid Cells 2 in Neurological Diseases.The European journal of neuroscience · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triggering receptor expressed on myeloid cells 2 (TREM2) is a key regulator of microglial and peripheral myeloid cell function, with its soluble form (sTREM2) emerging as a biomarker of neuroinflammation. Although cerebrospinal fluid (CSF) sTREM2 is consistently elevated in neurodegenerative diseases, the clinical relevance of blood sTREM2 remains unclear. We performed a retrospective observational study including 547 individuals: Alzheimer's disease (AD, n = 142), mild cognitive impairment (MCI, n = 42), multiple sclerosis (MS, n = 105), hereditary transthyretin amyloidosis with polyneuropathy (ATTR-PN, n = 23), asymptomatic ATTR mutation carriers (n = 25), and controls (n = 210). Plasma sTREM2 concentrations were measured using Lumipulse automated chemiluminescent enzyme immunoassay platform (Fujirebio, Tokyo, Japan). Age-adjusted multivariate analysis was performed to compare disease groups with controls. In controls, plasma sTREM2 levels increased with age, with a significant breakpoint at 68 years, after which the rate of increase markedly accelerated. Across diagnostic groups, AD, MCI, and MS patients exhibited significantly lower plasma sTREM2 levels (11%-18% reduction) compared to controls (p < 0.05), independent of age. No significant differences were observed in ATTR-PN patients or asymptomatic carriers. Age remained a strong positive predictor of sTREM2 levels across all groups. In conclusions, plasma sTREM2 levels are reduced in AD, MCI, and MS despite known elevations in CSF, indicating a divergence between peripheral and central TREM2 biology. The lack of alteration in ATTR-PN suggests tissue-specific regulation of sTREM2. These findings highlight that blood sTREM2 does not directly mirror central nervous system microglial activation but may reflect peripheral immune dynamics, warranting further investigation into its role as a biomarker of systemic immune dysfunction in neurodegenerative diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.